Shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) have been given an average broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company. Sonoma Pharmaceuticals’ rating score has declined by 100% from three months ago as a result of a number of analysts’ ratings changes.

Brokers have set a twelve-month consensus target price of $9.00 for the company and are anticipating that the company will post ($0.65) EPS for the current quarter, according to Zacks. Zacks has also given Sonoma Pharmaceuticals an industry rank of 173 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

SNOA has been the subject of several analyst reports. Maxim Group set a $7.00 price objective on Sonoma Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, February 8th. Benchmark initiated coverage on Sonoma Pharmaceuticals in a research report on Thursday, December 28th. They set a “speculative buy” rating and a $10.00 price target for the company. Finally, Zacks Investment Research upgraded Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a research report on Friday, January 19th.

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Deutsche Bank AG purchased a new position in shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 25,141 shares of the company’s stock, valued at approximately $137,000. Deutsche Bank AG owned 0.54% of Sonoma Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 13.24% of the company’s stock.

Shares of Sonoma Pharmaceuticals stock opened at $3.92 on Friday. Sonoma Pharmaceuticals has a fifty-two week low of $3.50 and a fifty-two week high of $7.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.83 and a current ratio of 4.62.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings data on Wednesday, February 7th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.10). The business had revenue of $4.84 million during the quarter, compared to analysts’ expectations of $4.50 million. Sonoma Pharmaceuticals had a negative return on equity of 70.95% and a negative net margin of 70.46%. equities research analysts anticipate that Sonoma Pharmaceuticals will post -2.86 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.dailypolitical.com/2018/04/17/zacks-sonoma-pharmaceuticals-snoa-receives-consensus-recommendation-of-buy-from-brokerages.html.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains.

Get a free copy of the Zacks research report on Sonoma Pharmaceuticals (SNOA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.